Advertisement
UK markets close in 5 hours 55 minutes

  • FTSE 100

    8,108.75
    +29.89 (+0.37%)
     

  • FTSE 250

    19,840.14
    +238.16 (+1.21%)
     

  • AIM

    755.93
    +2.81 (+0.37%)
     

  • GBP/EUR

    1.1656
    -0.0001 (-0.01%)
     

  • GBP/USD

    1.2510
    -0.0001 (-0.01%)
     

  • Bitcoin GBP

    51,589.68
    +437.37 (+0.86%)
     

  • CMC Crypto 200

    1,390.88
    -5.66 (-0.40%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    83.80
    +0.23 (+0.28%)
     

  • GOLD FUTURES

    2,361.90
    +19.40 (+0.83%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,038.27
    +120.99 (+0.68%)
     

  • CAC 40

    8,025.22
    +8.57 (+0.11%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Is Merck & Co. (MRK) Outperforming Other Medical Stocks This Year?

Zacks Equity Research
Updated
Northern Trust (NTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Merck & Co. (MRK) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

Merck & Co. is one of 763 individual stocks in the Medical sector. Collectively, these companies sit at #11 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. MRK is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for MRK's full-year earnings has moved 1.65% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

ADVERTISEMENT

Based on the most recent data, MRK has returned 10.06% so far this year. At the same time, Medical stocks have gained an average of 1.09%. This means that Merck & Co. is outperforming the sector as a whole this year.

Looking more specifically, MRK belongs to the Large Cap Pharmaceuticals industry, which includes 14 individual stocks and currently sits at #108 in the Zacks Industry Rank. Stocks in this group have lost about 2.06% so far this year, so MRK is performing better this group in terms of year-to-date returns.

MRK will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.